Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.24.1.u1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents [note 6] $ 66,398 $ 15,546
Grant receivable [note 3]   111
Prepaid expenses and other assets 1,311 1,325
Total current assets 67,709 16,982
Right-of-use assets [note 9] 51 66
Other assets and restricted cash [note 6] 94 92
License agreement [note 4 and note 5] 1,141 1,197
Goodwill 1,034 1,034
Total assets 70,029 19,371
Current liabilities:    
Accounts payable 373 618
Accrued liabilities other 1,037 351
Contingent consideration [note 5 and note 6] 580 528
Accrued clinical liabilities 525 280
Accrued compensation 864 2,311
Current portion of long-term obligations [note 9] 53 63
Convertible debt [note 6 and note 7] 17,141 16,662
Total current liabilities 20,573 20,813
Long-term obligations [note 9]   6
Total liabilities 20,573 20,819
Commitments and contingencies [note 9]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,251,911 issued and outstanding at March 31, 2024 and 21,165,760 issued and outstanding at December 31, 2023 103 90
Additional paid-in capital 221,594 164,209
Accumulated deficit (172,245) (165,751)
Accumulated other comprehensive income 4 4
Total stockholders' equity 49,456 (1,448)
Total liabilities and stockholders' equity 70,029 19,371
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value